Skip to main content

Series A · 2026-11-05 · Healthcare

Alethio Therapeutics raises $86.9M

71
AI Score
Amount
$86.9M
Round
Series A
Lead
Sofinnova Partners, RA Capital
HQ
Abingdon-on-Thames, GB
Why it matters: The round's syndicate and the ATX-011 timeline show how a University of Oxford spin-out is moving a targeted MPN antibody toward Phase 1/2a.

Alethio Therapeutics, an Abingdon-on-Thames biopharma spun out of the University of Oxford in 2021.

Participants:
Oxford Science Enterprises, Cancer Research Horizons, University of Oxford

Deal Dossier PRO

Pro feature
Deal Dossier for Alethio Therapeutics

Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.

Generate dossier — Pro
Already Pro? Sign in · See plans

Figures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).

More deals with Sofinnova Partners

Recent Healthcare rounds

Browse all deals in the funding database →

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing